2008
DOI: 10.1521/bumc.2008.72.3.163
|View full text |Cite
|
Sign up to set email alerts
|

Identifying clinical cases among patients assigned to psychoanalytic treatment

Abstract: [163][164][165][166][167][168][169][170][171][172][173][174][175][176][177][178] Although several countries (e.g., Norway, Belgium, Germany, Canada, The Netherlands) provide government funding for long-term

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
10
0
3

Year Published

2009
2009
2016
2016

Publication Types

Select...
7

Relationship

4
3

Authors

Journals

citations
Cited by 13 publications
(14 citation statements)
references
References 30 publications
1
10
0
3
Order By: Relevance
“…Encouraged by the low‐dose efficiency in preclinical tests, we investigated here the effects of 20 mg (1 × 20 mg) and 40 mg (2 × 20 mg) E. angustifolia extract on anxiety in healthy volunteers. Although the STAI has no established thresholds, the cut‐off value of 45 points (the threshold for inclusion in this study) has been employed in many similar studies and is considered to be the threshold for clinically significant levels of anxiety (Tominaga et al ., ; Berghout and Zevalkink, ; Dyson et al ., ). Based on studies where anxiety was evaluated by both the STAI and the Hamilton Anxiety Scale (Alpsoy et al ., ; Laakmann et al ., ; Andreatini et al ., ; De Candia et al ., ;), we suggest that our subjects showed mild, but clinically relevant levels of anxiety.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Encouraged by the low‐dose efficiency in preclinical tests, we investigated here the effects of 20 mg (1 × 20 mg) and 40 mg (2 × 20 mg) E. angustifolia extract on anxiety in healthy volunteers. Although the STAI has no established thresholds, the cut‐off value of 45 points (the threshold for inclusion in this study) has been employed in many similar studies and is considered to be the threshold for clinically significant levels of anxiety (Tominaga et al ., ; Berghout and Zevalkink, ; Dyson et al ., ). Based on studies where anxiety was evaluated by both the STAI and the Hamilton Anxiety Scale (Alpsoy et al ., ; Laakmann et al ., ; Andreatini et al ., ; De Candia et al ., ;), we suggest that our subjects showed mild, but clinically relevant levels of anxiety.…”
Section: Discussionmentioning
confidence: 99%
“…the cut‐off score was 46 at each subscale). This approach and similar cut‐off scores were amply employed earlier (Tominaga et al ., ; Berghout and Zevalkink, ; Dyson et al ., ). Exclusion criteria were as follows: any diagnosed DSM‐IV Axis I disorder and/or psychotropic medication during the 6 months that preceded the study, DSM‐IV personality disorder, suicidal risk as judged by the investigator (JZ, JF), participation in psychotherapy during the 3 months that preceded the study, allergy towards plants of the family Asteraceae, and pregnancy.…”
Section: Methodsmentioning
confidence: 99%
“…Cronbach’s α = .96 for the 90 items at baseline (Scogin et al, 2007). Researchers have demonstrated the GSI is a valid measure of general PD (Berghout & Zevalkink, 2008; Hafkenscheid, 1993). …”
Section: Methodsmentioning
confidence: 99%
“…De gemiddelde effectgroottes bleken in de PAgroep vooral voor de persoonlijkheidsinstrumenten iets hoger uit te vallen dan in de PP-groep. Uit eerder onderzoek (Berghout & Zevalkink, 2008;Zevalkink & Berghout, 2008b, 2008c kwam naar voren dat bij de gevolgde patiënten inderdaad sprake is van forse en langdurige problematiek: zij werden door (chronische) depressiviteit, interpersoonlijke problemen en (angstige) persoonlijkheidspathologie en ongeveer 70% van de patiënten had eerder kortdurende behandelingen geprobeerd zonder voldoende succes. Symptoomvermindering wordt doorgaans niet gezien als een belangrijk doel van langdurige psychoanalytische behandelingen (Blatt & Auerbach, 2003;Galatzer-Levy, Bachrach, Skolnikoff & Waldron, 2000;Kantrowitz, Katz, Paolitto, Sashin & Solomon, 1987).…”
Section: Discussieunclassified